Get Premium to unlock powerful stock data

Mariko Gordon Nearly Doubles Stake in Forward Air

Gordon's 3rd quarter holding increases

Author's Avatar
Jan 04, 2016
Article's Main Image

The following are the stocks that

Mariko Gordon (Trades, Portfolio) increased her stakes in during the third quarter. Gordon is the founder of Daruma Capital Management. She started the firm in 1995 with zero assets and now her portfolio is composed of 48 stocks with a total value of $1.6 billion.

The largest increase was Forward Air Corp. (FWRD). Gordon increased her stake by 90.85% with an impact of 1.56% on the portfolio, reaching a total of more than 1.2 million shares. The current stake is 3.27% of the company’s outstanding shares.

Operating revenue for the third quarter grew by 22.6% year over year, and as a percent of operating revenue, income from operations was 7.5%, compared with 12.5% in the same period last year.

GuruFocus gives Forward Air a profitability and growth rating of 7/10; its profitability ratios and returns are positive. ROE is 10.43%, ROA is 7.73%, operating margin is 8.55%, net margin is 5.39% and they are outperforming 53% of the Global Integrated Shipping & Logistics industry.

Chuck Royce (Trades, Portfolio) is largest shareholder of the company among the gurus with 8.48% of outstanding shares, followed by Columbia Wanger (Trades, Portfolio) with 4.64% and Jim Simons (Trades, Portfolio) with 0.44%.

The second largest increase was Pacira Pharmaceuticals Inc. (PCRX). The fund increased shares by 56.02% with an impact of 0.94% on its total assets.

The company is a pharmaceutical company engaged in the development, commercialization and manufacture of proprietary pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. During the third quarter, EXPAREL revenues grew 19% over the same period last year and the company ended the third quarter of 2015 with cash and cash equivalents, short-term investments and long-term investments of $164.4 million.

Pacira Pharmaceuticals has a GuruFocus profitability and growth rating of 3/10; its profitability ratios and returns are positive. ROE is 5.55%, ROA is 3%, operating margin is 7.53%, net margin is 4.21% and they are underperforming 52% of the Global Drug Manufacturers - Specialty & Generic industry.

Gordon is the largest guru shareholder followed by

Jim Simons (Trades, Portfolio) with 0.3% of shares outstanding, Paul Tudor Jones (Trades, Portfolio) with 0.02% and Ron Baron (Trades, Portfolio) 0.02%.

Gordon increased by 30.44% her stake in SunOpta Inc. (STKL) with an impact of 0.46% on the portfolio. The current stake is 7.82% of the company’s outstanding shares and 1.99% of the investor’s total assets.

The company is engaged in natural, organic and specialty foods and natural health products. The company specializes in sourcing, processing and packaging of natural and organic food products, integrated from seed through packaged products. In the third quarter, operating income was 2% of revenues, compared to 4% of revenues in the third quarter of 2014. Revenues had a decrease of 0.6%.

GuruFocus gives SunOpta a profitability and growth rating of 6/10. Its profitability ratios and returns are weak, as ROE is 1.65%, ROA is 0.87%, operating margin is 1.59%, net margin is 0.49% and they are underperforming 70% of the Global Packaged Foods industry.

Gordon is largest shareholder of the company among the gurus, followed by

Chuck Royce (Trades, Portfolio) with 2.8%, Jim Simons (Trades, Portfolio) with 0.79% and Mario Gabelli (Trades, Portfolio) with 0.04%.

Gordon increased by 45.34% the stake in Belden Inc. (BDC) with an impact of 0.07% on the portfolio. The current stake is 0.18% of outstanding shares and 0.22% of the fund's total assets.

The company is a signal transmission solutions provider built around four business platforms: Broadcast Solutions, Enterprise Connectivity Solutions, Industrial Connectivity Solutions, and Industrial IT Solutions. During the third quarter, gross profit margins was 39.0%, increasing 270 basis points from 36.3% in the year-ago period, and adjusted EBITDA margins was 16.5%, increasing 80 basis points from 15.7% in the year-ago period.

GuruFocus gives Belden a profitability and growth rating of 2/10. Its profitability ratios and returns are weak, as ROE is 4.03%, ROA is 0.97%, operating margin is 5.46%, net margin is 1.40% and they are underperforming the 64% of the Global Electronic Components industry.

The company’s largest shareholder among the gurus is

Scott Black (Trades, Portfolio) with 0.26% of outstanding shares, then Mario Gabelli (Trades, Portfolio) with 0.08% and David Dreman (Trades, Portfolio) with 0.01%.

Gordon increased by 19.26% her stake in Sensient Technologies Corp. (SXT) with an impact of 0.03% on the portfolio. The current stake is 0.19% of the investor’s total assets.

The company is a manufacturer and marketer of colors, flavors and fragrances. The company uses technologies at facilities to develop specialty food and beverage systems, cosmetic and pharmaceutical systems, inkjet and specialty inks and colors, and other specialty chemicals.

GuruFocus gives Sensient Technologies a profitability and growth rating of 6/10. Its profitability ratios and returns are good, as ROE is 11.57%, ROA is 6.46 %, operating margin is 12.39%, net-margin is 8.19% and they are outperforming 69% of the Global Specialty Chemicals industry.

Mario Gabelli (Trades, Portfolio) is largest shareholder of the company among the gurus with 2% of outstanding shares, followed by John Keeley (Trades, Portfolio) with 1.3%, Robert Olstein (Trades, Portfolio) with 0.29% and Jim Simons (Trades, Portfolio) with 0.13%.

The fund increased by 10.55% its stake in Bruker Corp. (BRKR) with an impact of 0.02% on its portfolio. The current stake is 0.22% of Gordon’s total assets.

The company is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of customers in life science, pharmaceutical, biotechnological, clinical and molecular diagnostics research, and materials and chemical analysis in various industries and government applications. Revenues for the third quarter of 2015 had a decline of 5.6% compared to the third quarter of 2014, and non-GAAP EPS increased by 36% compared to the same quarter of a year before.

GuruFocus gives Bruker a profitability and growth rating of 2/10. Its profitability ratios and returns are positive. ROE is 8.70%, ROA is 3.60%, operating margin is 7.23%, net margin is 4.01% and they are outperforming 64% of the Global Diagnostics & Research industry.

The company’s largest shareholder among the gurus is

Vanguard Health Care Fund (Trades, Portfolio) with 2.28% of outstanding shares, followed by NWQ Managers (Trades, Portfolio) with 1.08% and Ray Dalio (Trades, Portfolio) with 0.02%.

Also check out:
Rating:
4 / 5 (1 votes)

GuruFocus Screeners

Related Articles

Q&A with Gurus